In a recent development, Exicure, Inc. (Nasdaq: XCUR), a renowned biotechnology company with a focus on developing nucleic acid therapeutics, has received a delisting determination notice from The Nasdaq Stock Market LLC (Nasdaq). The company has failed to submit its Form 10-K for the year ended December 31, 2023, which is in violation of Nasdaq Listing Rule 5250(c)(1). This delisting determination places Exicure s listing status and future prospects under scrutiny.The Importance of Form 10-K:Form 10-K is a comprehensive annual report that provides an in-depth overview of a company s financial performance, operations, and potential risks. It serves as a crucial disclosure document for investors, analysts, an...

XCUR's Stock Performance relative to it's Customers

XCUR's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Exicure Inc	8.19	6.81	-9.78	8
SUBTOTAL	0.00	0.00	0.00	-

Sources: Exicure Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Exicure Inc’s corporate clients.
For your research, we’ve provided 9 tables on Exicure Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.